NOC 7

Drug Profile

NOC 7

Latest Information Update: 30 Apr 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Class Heart failure therapies; Hydrazines; Small molecules; Vasodilators
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Heart failure; Ischaemic heart disorders

Most Recent Events

  • 12 Aug 1998 Two preclinical studies have been added to the Heart Failure and Ischaemic Heart Disease pharmacodynamics sections ,
  • 30 Dec 1996 Preclinical development for Heart failure in Japan (Unknown route)
  • 18 Dec 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top